Analysis | Metabolite Name | Measured Value | Units | Sample | TREATMENT |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.645 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7379 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7733 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.7996 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8122 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.827 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8604 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.8723 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9008 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.9224 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.946 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 0.994 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.006 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0212 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0348 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0476 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0544 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.0853 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.149 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.1885 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2175 | Peak area | Plasma | Saline |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.2984 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.3308 | Peak area | Plasma | Angiotensin II |
Reversed phase NEGATIVE ION MODE | 1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6) | 1.4206 | Peak area | Plasma | Angiotensin II |